Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / App Notes / 2021 / A single NGS workflow for comprehensive genomic profiling

A single NGS workflow for comprehensive genomic profiling

02/23/2021

Share

 

Analysis of simple and complex variants and biomarkers for comprehensive genomic profiling using a single NGS workflow for FFPE and cfDNA samples.

 

 

Introduction: Current comprehensive genomic profiling (CGP) approaches are challenging as they require two separate eluates and a minimum of two workflows, one for DNA and another for RNA. To overcome these challenges, we developed the QIAseq Pan Cancer Multimodal Panel, a streamlined, single workflow and integrated bioinformatics for the analysis of a wide range of variants and biomarkers for oncology research.

Methods: Panel performance was verified using FFPE and cfDNA reference samples from SeraCare. Tumor nucleic acid (TNA) from FFPE samples were extracted using modified QIAGEN protocols. TNA (20–50 ng) was used as input for library construction. Libraries were constructed using the Pan Cancer Panel workflow, quantified and sequenced either on a MiSeq® or NextSeq® instrument. FASTQ files were processed with preconfigured analysis pipelines using the QIAGEN® CLC Genomics Workbench.

Results: All variants in reference samples were detected.
DNA: Single-nucleotide variants (SNVs) and Insertions-Deletions (InDels) were detected in cfDNA samples at variant allele frequencies (VAF) <1% and in FFPE samples down to 1% VAF. Complex variants such as the CALR type-1 deletion (52-bp deletion) and FLT3 ITDs were also detected. The panel called two insertions in CEBPA, a GC-rich gene. Analysis of copy number variations (CNVs) showed that the panel can call CNVs at both the gene and exon levels by accurately calling six additional copies of the EGFR, MET and MYCN genes. Tumor mutational burden (TMB) scores were accurately called as ‘low’ or ‘high’ in the respective TMB reference samples.
RNA: All fusions, exon skipping (ES), and alternatively spliced variants (ASVs) covered by the panel were correctly called, including, but not limited to, NTRK1, NTRK2, NTRK3, BCR, ALK and RET fusions. The panel was designed to cover only one partner of all detected fusions.

Conclusion: These results provide proof-of-principle evidence that the QIAseq Pan Cancer Panel enables CGP from FFPE and cfDNA samples using a single workflow with TNA or DNA as input for both solid tumors and hematologic malignancies.

 

 

>> Download the Application Note as a PDF

 

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Fast and automated TSA-based multiplexed immunofluorescence on LabSat® Research

February 15, 2021

A single NGS workflow for comprehensive genomic profiling

February 23, 2021

Biomarker Optimization on LabSat® Research

March 23, 2021

Fully automated quantification of Meropenem, Tazobactam, Piperacillin and Dexamethasone in plasma

May 4, 2021

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.